Federated Hermes Inc. Purchases New Shares in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Federated Hermes Inc. purchased a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 20,407 shares of the company’s stock, valued at approximately $50,000.

A number of other hedge funds and other institutional investors have also modified their holdings of VTYX. Connor Clark & Lunn Investment Management Ltd. boosted its position in Ventyx Biosciences by 139.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 63,944 shares of the company’s stock worth $2,221,000 after acquiring an additional 37,240 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Ventyx Biosciences by 962.7% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 987,970 shares of the company’s stock worth $34,312,000 after acquiring an additional 895,000 shares during the period. Hudson Bay Capital Management LP boosted its position in Ventyx Biosciences by 160.2% during the 3rd quarter. Hudson Bay Capital Management LP now owns 248,515 shares of the company’s stock worth $8,631,000 after acquiring an additional 153,000 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Ventyx Biosciences by 42.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,385 shares of the company’s stock worth $12,620,000 after acquiring an additional 107,997 shares during the period. Finally, FMR LLC boosted its position in Ventyx Biosciences by 1.5% during the 3rd quarter. FMR LLC now owns 8,677,529 shares of the company’s stock worth $301,371,000 after acquiring an additional 124,298 shares during the period. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Trading Down 2.9 %

Shares of NASDAQ:VTYX opened at $4.71 on Tuesday. The stock has a market capitalization of $332.05 million, a P/E ratio of -1.43 and a beta of 0.48. Ventyx Biosciences, Inc. has a 1-year low of $1.87 and a 1-year high of $40.58. The business has a 50-day moving average price of $6.05 and a two-hundred day moving average price of $4.81.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Tuesday, February 27th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same quarter in the prior year, the firm posted ($0.62) EPS. As a group, equities analysts predict that Ventyx Biosciences, Inc. will post -2.55 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on VTYX shares. Lifesci Capital upgraded Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a report on Wednesday, February 28th. Wells Fargo & Company raised Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $7.00 to $16.00 in a research report on Tuesday, March 12th. Canaccord Genuity Group dropped their price target on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Finally, Oppenheimer raised Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research report on Tuesday, March 12th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.75.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.